Invitae Corporation (0JDB.L)
| Previous close | 0.6740 |
| Open | 0.6638 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.6638 - 0.6638 |
| 52-week range | 0.6357 - 3.7050 |
| Volume | |
| Avg. volume | 55,863 |
| Market cap | 605,780 |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0560 |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireInvitae Announces Appointment of Finance Veteran Ana Schrank as CFO
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.
- PR Newswire
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the "NYSE") on September 20, 2023, indicating the company is not currently in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock over a consecutive 30 trading-day period was less than $1.00 per share. The NYSE notice has no immediate effect on the listing of the common stock on the NYSE
- Investing.com
Invitae aims to regain NYSE compliance after average share price falls below $1
San Francisco-based medical genetics company, Invitae (NYSE:NVTA), received a notice from the New York Stock Exchange (NYSE) on Tuesday, indicating that the firm is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The violation was due to the average closing price of Invitae's common stock falling below $1.00 per share over a consecutive 30 trading-day period.
